Prescription medicine
Etuvetidigene autotemcel Brand names: Waskyra
Etuvetidigene autotemcel (Waskyra) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the etuvetidigene autotemcel FDA label on DailyMed (effective July 23, 2026); every etuvetidigene autotemcel label on DailyMed.
Highlights of the record
FDA label of July 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageWASKYRA ® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.
Forms and strengths
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is etuvetidigene autotemcel used for?
From the label: indications and usageWASKYRA ® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available. […]
Source: FDA drug label (WASKYRA), Fondazione Telethon ETS, effective July 23, 2026 (SPL set 45929c87-685d-b21c-e063-6394a90a3818), via openFDA; the full label on DailyMed
Is there a generic for etuvetidigene autotemcel (Waskyra)?
No generic etuvetidigene autotemcel is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the etuvetidigene autotemcel label say about other medicines?
The etuvetidigene autotemcel label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Rituximab | warnings and precautions | Increased susceptibility to infections may occur due to concomitant administration of rituximab and conditioning regimen. |
Source: FDA drug label (WASKYRA), Fondazione Telethon ETS, effective July 23, 2026 (SPL set 45929c87-685d-b21c-e063-6394a90a3818), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other